Hematopoiesis News Volume 5.27 | Jul 22 2014

DOCK2 Is Critical for CD8⁺ TCR^– Graft Facilitating Cells to Enhance Engraftment of Hematopoietic Stem and Progenitor Cells
Dedicator of cytokinesis 2 (DOCK2)^-/- facilitating cells exhibit compromised facilitative function in vivo as evidenced by the loss of engraftment-enhancing capability for c-Kit⁺Sca-1⁺lineage^– (KSL) cells, and compromised ability to promote KSL cell homing and lodgment in hematopoietic niche. [Stem Cells] Abstract

LincRNAs MONC and MIR100HG Act as Oncogenes in Acute Megakaryoblastic Leukemia
Researchers report that long non-coding RNAs MONC and MIR100HG are highly expressed in acute megakaryoblastic leukemia blasts. The transcripts were mainly localized in the nucleus and their expression correlated with the corresponding microRNA clusters. [Mol Cancer] Abstract | Full Article

Diet-Induced (Epigenetic) Changes in Bone Marrow Augment Atherosclerosis
Scientists investigated the long-term changes induced by Western-type diet (WTD) feeding on BM cells and the consequences for atherosclerosis susceptibility. Hereto, WTD BM or Chow BM was transplanted into LDLR KO mice on chow. BM from WTD BM recipient mice exhibited hypomethylation of CpG regions in the genes encoding Pu.1 and IRF8, key regulators of monocyte proliferation and macrophage differentiation. [J Leukoc Biol] Abstract

Dietary Restriction Ameliorates Hematopoietic Aging Independent of Telomerase, whilst Lack of Telomerase and Short Telomeres Exacerbate the Aging Phenotype
To investigate the role of telomeres and telomerase in hematopoietic aging, investigators compared the hematopoietic stem and progenitor cell profile and clonogenic capacity of bone marrow cells from wild type with telomerase-deficient mice and the effect of dietary restriction on these parameters. [Exp Gerontol] Abstract

CLINICAL RESEARCH

The EBMT/EMCL Consensus Project on the Role of Autologous and Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma
Investigators conducted a consensus project using the RAND modified Delphi consensus procedure to provide guidance on how stem cell transplantation should be employed in mantle cell lymphoma. [Leukemia] Abstract

Chromosome 1 Abnormalities in Newly Diagnosed Elderly Multiple Myeloma Patients Treated with Novel Therapies
Researchers investigated the impact of chromosome 1 abnormalities in a group of elderly newly diagnosed Multiple Myeloma patients, enrolled in the GIMEMA-MM-03-05 trial and treated with bortezomib, melphalan and prednisone vs bortezomib, melphalan, prednisone and thalidomide followed by bortezomib and thalidomide maintenance. [Haematologica] Abstract | Full Article

Allogeneic Hematopoietic SCT in Combination with Tyrosine Kinase Inhibitor Treatment Compared with TKI Treatment Alone in CML Blast Crisis
Of 83 CML blast crisis patients, 45 received tyrosine kinase inhibitors (TKIs) (imatinib; nilotinb or dasatinib after imatinib resistance) and 38 were treated with allo-HSCT after TKI. [Bone Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Synta Announces Advancement of Ganetespib into Phase III Extension of AML LI-1 Study for Patients with AML and High-Risk MDS
Synta Pharmaceuticals Corp. announced the advancement of ganetespib into the Phase III extension of the AML LI-1 (less intensive) trial. AML LI-1 is a multicenter, randomized Phase II/III clinical study evaluating several novel treatment regimens, including the combination of ganetespib with low dose cytarabine, in newly diagnosed elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are not eligible for intensive chemotherapy. [Synta Pharmaceuticals Corp.] Press Release

ERYTECH Announces Enrollment of First Patient in Phase I/II Study of ERY-ASP in Acute Lymphoblastic Leukemia in the United States
ERYTECH Pharma announced the enrollment of the first patient in its Phase I/II study with ERY-ASP in acute lymphoblastic leukemia in the United States of America. [ERYTECH Pharma] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW Senior Research Fellow/Research Fellow – Hematopoietic and Leukemia Stem Cell Biology (Monash University)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Postdoctoral Research Fellow – Molecular Mechanisms Regulating Transformation and Maintenance of Leukemia Stem Cells (City of Hope)

PhD Student – Development and Regulation of Innate Immunity (Lund University)

Biologist – Hypoxia Signaling in Myeloproliferative Neoplasms (University Hospital Aachen)

Research Associate – Transcriptional/Epigenetic Changes and Their Roles in Normal and Malignant Hematopoietic Stem Cell Development (King’s College London)

Scientific Manager – hES and iPS Cell Lines to Model Normal Hematopoiesis and Related Blood Diseases (St. Jude Children’s Research Hospital)

Postdoctoral Research Fellow – Cardiovascular Immunology / Hematology (Massachusetts General Hospital)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.